{name}
{subtitle}
Efficacy, Safety, and Tolerability of V937 Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)
city
~19 mi. (La Tronche, France, +25 more cities)
facility
CHU de Grenoble Hopital Nord ( Site 2027)
drug
coxsackievirus A21, +1 more drug
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~47 mi. (Valence, France, +137 more cities)
facility
Centre Hospitalier de Valence-Service de Dermatologie ( Site 0377)
FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation
city
~68 mi. (Sainte-Colombe, France, +41 more cities)
facility
Clinique Trenel
drug
fluorouracil, +3 more drugs
drug type
chemotherapy, +2 more types
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~82 mi. (Pierre-Bénite, France, +144 more cities)
facility
CH Lyon Sud Hospices Civils de Lyon ( Site 1203)
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
city
~82 mi. (Pierre-Bénite, France, +176 more cities)
facility
Centre Hospitalier Lyon Sud ( Site 2064)
condition
Endometrial Carcinoma, +1 more condition
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~82 mi. (Pierre-Bénite, France, +226 more cities)
facility
C.H.U. Lyon Sud ( Site 0436)
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
city
~82 mi. (Pierre-Bénite, France, +147 more cities)
facility
Centre Hospitalier Lyon Sud ( Site 0413)
condition
Cervical Adenocarcinoma, +2 more conditions
drug
brachytherapy, +3 more drugs
drug type
chemotherapy, +2 more types
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
city
~82 mi. (Pierre-Bénite, France, +163 more cities)
facility
C.H.U. Lyon Sud ( Site 0466)
drug
cystectomy, +2 more drugs
drug type
chemotherapy, +3 more types